During the webinar Smarter Planning for Better Decisions in the Pharma and Biotech industry, we explored the key challenges and developments shaping financial planning in the life sciences sector. This edition highlights how finance teams can navigate scientific uncertainty while maintaining agility, control, and reliable insights across the organization. On this page you can revisit all sessions from the event.
In today’s pharma and biotech landscape, financial planning has become a strategic function guiding decisions from early R&D to market launch. Unpredictable R&D spending, scattered data, and high-stakes product launches demand a planning approach that combines scientific insight with strong analytics and agility. With integrated data models, the right tooling, and well-structured FP&A teams, finance organizations can move from reactive forecasting to confident, insight-driven decision-making. This session shows how leading companies achieve this and helps you assess your FP&A maturity and the steps toward a more integrated, strategically aligned planning process.
What did we discuss in this webinar
Financial planning requires the right mix of science, agility, and control – from R&D to market launch. In this focused session, we show how improved data models, tooling, and team setups enable faster decision-making for your pharma or biotech organization.
Here’s what we will cover:
- Clear framing & engagement – Why financial planning in pharma requires a unique mix of science, agility, and control, from R&D to market launch.
- Real-life insights & inspiration – How proven data models, tooling, and team setups accelerate decision-making, shared through real project experiences.
- Recognize your own FP&A level – Use the Finext FP&A Maturity Model to identify where your organization stands and what steps lead to an integrated, insight-driven planning process.
This webinar is designed for CFOs, Finance Directors, and FP&A Managers at pharma, biotech, and CDMO companies across Germany, the Nordics, the Netherlands, and the UK.
